Corona Remedies Revenue and Competitors
Estimated Revenue & Valuation
- Corona Remedies's estimated annual revenue is currently $336.7M per year.
- Corona Remedies's estimated revenue per employee is $192,056
Employee Data
- Corona Remedies has 1753 Employees.
- Corona Remedies grew their employee count by 27% last year.
Corona Remedies's People
Name | Title | Email/Phone |
---|
Corona Remedies Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $46.2M | 221 | 16% | N/A | N/A |
#2 | $43.8M | 218 | 21% | N/A | N/A |
#3 | $57.1M | 284 | 26% | N/A | N/A |
#4 | $24.5M | 91 | -10% | N/A | N/A |
#5 | $52.9M | 263 | 13% | N/A | N/A |
#6 | $24.7M | 123 | 13% | N/A | N/A |
#7 | $1.8M | 16 | -6% | $114.3M | N/A |
#8 | $7.2M | 28 | -7% | N/A | N/A |
#9 | $13.7M | 51 | -9% | N/A | N/A |
#10 | $7.6M | 39 | -13% | $123.9M | N/A |
What Is Corona Remedies?
N/A
Total Funding
1753
Number of Employees
$336.7M
Revenue (est)
27%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Corona Remedies News
2022-04-06 - Fatigue after COVID is way more than just feeling tired. 5 tips on what to do about it
So, understandably, there has been concern around the coronavirus potentially triggering chronic fatigue syndrome. Read more: Explainer: what is...
2022-03-30 - Effect of Early Treatment with Ivermectin among Patients with Covid ...
Although vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19)...
2022-03-22 - Treatments for coronavirus (COVID-19)
The NHS is offering antibody and antiviral treatments to people with coronavirus (COVID-19) who are at highest risk of becoming seriously ill. The treatments...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $602M | 1755 | N/A | N/A |
#2 | $590.8M | 1756 | 2% | N/A |
#3 | $799.4M | 1757 | 7% | N/A |
#4 | $474.9M | 1763 | 14% | N/A |
#5 | $644.3M | 1766 | -3% | N/A |